July 10, 2019 10:28 AM EDT

Sanofi begins countdown for FDA isatuximab review; Cirrhosis-focused biotech presents another mini IPO

Amber Tong

→ Sanofi has a milestone to celebrate today with its top late-stage prospect isatuximab as the FDA accepts the BLA for review. Positioned as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi begins countdown for FDA isatuximab review; Cirrhosis-focused biotech presents another mini IPO

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bristol Myers launches fresh round of major cost cuts in bid to get ahead of patent cliff

Lilly posts 45% sales jump, culls four programs across obesity, Alzheimer's, heart failure and eczema

AstraZeneca offers some detail on China probe, reaffirms commitment to that market

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

Kura's AML drug passes key study in advanced patients, plans next steps with FDA and newly diagnosed studies

Small personalized vaccine trial sees progress in late-stage kidney cancer

Sanofi be­gins count­down for FDA isat­ux­imab re­view; Cir­rho­sis-fo­cused biotech presents an­oth­er mi­ni IPO

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Sanofi begins countdown for FDA isatuximab review; Cirrhosis-focused biotech presents another mini IPO